Cargando…

Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT

We here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on <sup>11</sup>C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change i...

Descripción completa

Detalles Bibliográficos
Autores principales: Kitajima, Kazuhiro, Yamamoto, Shingo, Fujiwara, Masayuki, Kawanaka, Yusuke, Yamada, Yusuke, Nagasawa, Seiji, Shimatani, Kimihiro, Hanasaki, Takeshi, Taguchi, Motohiro, Kanematsu, Akihiro, Yamakado, Koichiro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: S. Karger AG 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077372/
https://www.ncbi.nlm.nih.gov/pubmed/33976628
http://dx.doi.org/10.1159/000514191
_version_ 1783684870784942080
author Kitajima, Kazuhiro
Yamamoto, Shingo
Fujiwara, Masayuki
Kawanaka, Yusuke
Yamada, Yusuke
Nagasawa, Seiji
Shimatani, Kimihiro
Hanasaki, Takeshi
Taguchi, Motohiro
Kanematsu, Akihiro
Yamakado, Koichiro
author_facet Kitajima, Kazuhiro
Yamamoto, Shingo
Fujiwara, Masayuki
Kawanaka, Yusuke
Yamada, Yusuke
Nagasawa, Seiji
Shimatani, Kimihiro
Hanasaki, Takeshi
Taguchi, Motohiro
Kanematsu, Akihiro
Yamakado, Koichiro
author_sort Kitajima, Kazuhiro
collection PubMed
description We here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on <sup>11</sup>C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change induced by the treatment effect and to determine the viability of bone metastases, regardless of whether sclerosis was present or not. Because one case demonstrated disappearance of abnormal <sup>11</sup>C-choline uptake of osteoblastic metastatic lesions after abiraterone therapy and no new lesions at other sites, suggesting nonviable bone metastases, we can assume a complete metabolic response. Because the other case demonstrated a decrease in the existing, abnormal <sup>11</sup>C-choline uptake of osteoblastic metastatic lesions, but multiple new appearances of osteoblastic and nonosteoblastic lesions with abnormal <sup>11</sup>C-choline uptake after radium-223 therapy suggesting multiple viable bone metastases, we can assume progressive metabolic disease. <sup>11</sup>C-choline PET/CT could help in assessing the treatment response of bone metastases in patients with metastatic CRPC.
format Online
Article
Text
id pubmed-8077372
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher S. Karger AG
record_format MEDLINE/PubMed
spelling pubmed-80773722021-05-10 Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT Kitajima, Kazuhiro Yamamoto, Shingo Fujiwara, Masayuki Kawanaka, Yusuke Yamada, Yusuke Nagasawa, Seiji Shimatani, Kimihiro Hanasaki, Takeshi Taguchi, Motohiro Kanematsu, Akihiro Yamakado, Koichiro Case Rep Oncol Case Report We here report 2 cases of castration-resistant prostate cancer (CRPC) observed two times on <sup>11</sup>C-choline positron emission tomography computed tomography (PET/CT), which was useful to discriminate viable progressive osteoblastic bone metastasis from benign osteoblastic change induced by the treatment effect and to determine the viability of bone metastases, regardless of whether sclerosis was present or not. Because one case demonstrated disappearance of abnormal <sup>11</sup>C-choline uptake of osteoblastic metastatic lesions after abiraterone therapy and no new lesions at other sites, suggesting nonviable bone metastases, we can assume a complete metabolic response. Because the other case demonstrated a decrease in the existing, abnormal <sup>11</sup>C-choline uptake of osteoblastic metastatic lesions, but multiple new appearances of osteoblastic and nonosteoblastic lesions with abnormal <sup>11</sup>C-choline uptake after radium-223 therapy suggesting multiple viable bone metastases, we can assume progressive metabolic disease. <sup>11</sup>C-choline PET/CT could help in assessing the treatment response of bone metastases in patients with metastatic CRPC. S. Karger AG 2021-03-22 /pmc/articles/PMC8077372/ /pubmed/33976628 http://dx.doi.org/10.1159/000514191 Text en Copyright © 2021 by S. Karger AG, Basel https://creativecommons.org/licenses/by-nc/4.0/This article is licensed under the Creative Commons Attribution-NonCommercial-4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission.
spellingShingle Case Report
Kitajima, Kazuhiro
Yamamoto, Shingo
Fujiwara, Masayuki
Kawanaka, Yusuke
Yamada, Yusuke
Nagasawa, Seiji
Shimatani, Kimihiro
Hanasaki, Takeshi
Taguchi, Motohiro
Kanematsu, Akihiro
Yamakado, Koichiro
Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT
title Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT
title_full Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT
title_fullStr Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT
title_full_unstemmed Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT
title_short Accurate Monitoring of the Response of Bone Metastases to Treatment in Patients with Prostate Cancer Using Choline PET/CT
title_sort accurate monitoring of the response of bone metastases to treatment in patients with prostate cancer using choline pet/ct
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8077372/
https://www.ncbi.nlm.nih.gov/pubmed/33976628
http://dx.doi.org/10.1159/000514191
work_keys_str_mv AT kitajimakazuhiro accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct
AT yamamotoshingo accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct
AT fujiwaramasayuki accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct
AT kawanakayusuke accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct
AT yamadayusuke accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct
AT nagasawaseiji accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct
AT shimatanikimihiro accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct
AT hanasakitakeshi accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct
AT taguchimotohiro accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct
AT kanematsuakihiro accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct
AT yamakadokoichiro accuratemonitoringoftheresponseofbonemetastasestotreatmentinpatientswithprostatecancerusingcholinepetct